Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Hologic (HOLX) and Arbutus Biopharma (ABUS)

TipRanksMay 8 12:41

Arbutus to Participate in Two Upcoming Investor Conferences

WARMINSTER, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a fu

Arbutus BiopharmaMay 7 12:00

The Arbutus Biopharma Corporation (NASDAQ:ABUS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Last week saw the newest quarterly earnings release from Arbutus Biopharma Corporation (NASDAQ:ABUS), an important milestone in the company's journey to build a stronger business. Revenues fell

Simply Wall StMay 5 20:37

Global RNAi Therapeutics Market Insights & Forecasts With Potential Impact of COVID-19 2024-2028 Featuring Sanofi, Alnylam, Arrowhead, Arbutus Biopharma, Benitec Biopharma, Sirnaomics - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global RNAi Therapeutics Market (By Molecule Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been add

BusinesswireMay 3 21:35

Chardan Capital Reiterates Buy on Arbutus Biopharma, Maintains $4 Price Target

Chardan Capital analyst Keay Nakae reiterates Arbutus Biopharma with a Buy and maintains $4 price target.

Analyst UpgradesMay 3 21:21

Analysts Have Conflicting Sentiments on These Healthcare Companies: Arbutus Biopharma (ABUS), Neurocrine (NBIX) and Bausch Health Companies (BHC)

TipRanksMay 3 19:11